Flamingo Therapeutics

Foundation date

04/07/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

The core business of Flamingo Therapeutics is the development of novel and innovative drugs for specific cancer types.

Upcoming events

Latest news

  • Latest field trials validate strength of Biotalys’ first biocontrol Evoca

    Thursday May 19th 2022

  • Belgian biotech in European Top-3 despite turbulent times

    Wednesday May 18th 2022

  • KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus

    Wednesday May 18th 2022

Jobs by Flamingo Therapeutics